MGMT and neoplasm: Taking into consideration the limitations of clinical scoring of MGMT methylation [20] and this retrospective analysis, future clinical trials should be designed to better control for variables like the time of sample fixation, tumor processing times, method for determining MGMT status [21], tumor location, anesthesia duration, as well as other comorbidities like patient age and sex.